Sheila Frame, the vice president of marketing, market access, and patient services at Sandoz, discusses US biosimilar policies in development and the impact they will have on the market at the World Biosimilar Congress 2020 at the Festival of Biologics USA in San Diego, California.
Sheila Frame is the vice president of marketing, market access, and patient services at Sandoz.
Transcript:
How do you think policy changes will affect the biosimilar market?
The great thing about the policy environment in the United States today is, finally, people are realizing that the current US system is not sustainable. Biosimilars offer such an obvious opportunity for immediate savingd that not only will help save the system, but also will improve access and certainly improve patient care. So, some of the policies that we're putting forward through the Biosimilars Forum relate to the experience that we've had in Europe and in Canada and in other countries, where you know that if you encourage incentives in the system, physicians and patients will adopt biosimilars much more quickly. We also know that most of the hospitals in the [Medicare] Part B space and in the medical benefits space really are trying to push quality and improve quality. So, quality star ratings in the United States, if these organizations adopt biosimilars quickly, should be given great credit. It's probably the one item that achieves complete bipartisan support in the United States. We've got 5 bills in front of Congress in the Senate right now that will definitely spur and encourage biosimilars. And finally, the balance and the opportunity that biosimilars create, to make space in the system for those important innovations that are coming through that are leading to cures in many of these areas. So, those are the policy areas that we're really advancing now, and I feel very confident and optimistic that we're going to see some movement in this regard this year.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.